Evommune (EVMN) Current Leases (2024 - 2026)

Evommune (EVMN) posted quarterly Current Leases of $1.3 million for Q1 2026, up 417.77% quarter-over-quarter from $242000.0 in Q4 2025.

Analysis

Evommune (EVMN) Current Leases (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Current Leases for 3 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

In Q1 2026, Current Leases changed N/A year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $242000.0, down 50.31% from the prior year.
Current Leases rose to $1.3 million in Q1 2026 per EVMN's latest filing, from $242000.0 in the prior quarter.
Across five years, Current Leases topped out at $1.3 million in Q1 2026 and bottomed at $160000.0 in Q3 2025.
Historically, Current Leases has averaged $535500.0 across 3 years, with a median of $364500.0 in 2024.
On a YoY basis, Current Leases climbed as much as 50.31% in 2025 and fell as far as 50.31% in 2025.
Evommune's Current Leases stood at $487000.0 in 2024, then tumbled by 50.31% to $242000.0 in 2025, then jumped by 417.77% to $1.3 million in 2026.
Business Quant data shows EVMN's Current Leases at $1.3 million in Q1 2026, $242000.0 in Q4 2025, and $160000.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	138.51 Bn	130.66 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.24 Bn	77.25 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	63.46 Bn	58.28 Bn	1.37 Bn	11.00 Mn
4	Moderna	57.89 Bn	52.75 Bn	52.00 Mn	-
5	Revolution Medicines	44.02 Bn	44.02 Bn	-	16.75 Mn
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn	21.95 Mn
7	Alnylam Pharmaceuticals	35.49 Bn	32.19 Bn	992.69 Mn	45.93 Mn
8	Royalty Pharma	28.43 Bn	27.59 Bn	-	-
9	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.27 Mn
10	Evommune	446.46 Mn	245.66 Mn	-	1.24 Mn

Historic Data

Download Data